Skip to main content
Premium Trial:

Request an Annual Quote

OriGene Raises $16M to Continue Building Antibody Collection

Premium

This story originally ran on March 18.

OriGene Technologies this week announced that it has raised $16 million in its completed Series B financing round.

The proceeds will be used to continue building the company's TrueMab monoclonal antibody collection. In a statement, OriGene said that it aims to build a monoclonal antibody collection that will cover the entire human genome of about 20,000 genes or most of the human proteome.

"The funding will propel us closer to meeting our goal," Wei-Wu He, OriGene's chairman and CEO, said.

IDG-Accel, SBI &TH Venture Capital Enterprise, and Zero2IPO led the round. Previous investors Morningside Venture Investments and President International Development also participated in the round.

According to OriGene, the TrueMab antibodies will be "significantly different" from other antibodies on the market. The company is using authentic human full-length proteins as immunogens in the manufacturing process. As a result, the TrueMab antibodies have been "proven far superior in quality" compared to small peptide-generated monoclonal and polyclonal antibodies, "especially in applications such as flow cytometry and multiplex ELISA assays," OriGene said.

In November, the Human Protein Atlas said it had adopted OriGene's Verify Tagged Antigen over-expression lysates, full-length human proteins for functional studies and antibody validation, and increased the validation success rate to 80 percent from 30 percent [See PM 11/13/09].

Based in Rockville, Md., OriGene calls itself a gene-centric life sciences firm. Its product line includes more than 5,000 purified human proteins and the world's largest cDNA and shRNA clone collections.

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.